Literature DB >> 7641153

Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.

B Hodges1.   

Abstract

OBJECTIVE: To examine the type and number of interactions of psychiatry residents, interns and clerks with sales representatives of pharmaceutical companies and the attitudes of physicians-in-training toward these interactions.
DESIGN: Survey conducted with the use of a self-report questionnaire.
SETTING: Seven teaching hospitals affiliated with the Department of Psychiatry, University of Toronto. PARTICIPANTS: All 105 residents, interns and clerks training in psychiatry at the seven teaching hospitals between October 1993 and February 1994 were eligible; 74 completed questionnaires, for a response rate of 70%. One respondent was excluded from the analysis. OUTCOME MEASURES: Number of personal meetings and "drug lunches" attended, number of drug samples and promotional items received and estimated value of gifts received by each physician-in-training during a 1-year period as well as attitudes of residents, interns and clerks about interactions with pharmaceutical representatives.
RESULTS: Median number of personal meetings reported was 1 (range 0 to 35), of drug lunches attended was 10 (range 0 to 70), of promotional items received was 2 (range 0 to 75) and of drug samples received was 1 (range 0 to 20). Trainees' median estimate of the value of gifts received was $20 (range $0 to $800 Fewer than one third felt that pharmaceutical representatives were a source of accurate information about drugs; however, 71% (52/73) disagreed with the statement that representatives should be banned from making presentations. Although only 15% (11/73) felt they had sufficient training about meeting with pharmaceutical representatives, 34% (25/73) felt that discussions with representatives would have no impact on their prescribing practices, and 56% (41/73) felt that receiving gifts would have no impact on prescribing. Fewer than half said they would maintain the same degree of contact with representatives if they did not receive promotional gifts. The more money and promotional items a physician-in-training had received, the more likely he or she was to believe that discussions with representatives did not affect prescribing (p < 0.05). Clerks, interns and junior (first-year and second-year) residents attended two to three times more drug lunches than senior (third-year and fourth-year) residents, and significantly more junior than senior residents felt that pharmaceutical representatives have a valuable teaching role. Junior residents were three times more likely than senior residents to have received drug samples.
CONCLUSIONS: Interactions between pharmaceutical representatives and psychiatry residents, interns and clerks are common. The physicians-in-training perceive little educational value in these contacts and many, especially clerks, interns and junior residents, disavow the potential of these interactions to influence prescribing. Therefore, supervisors of postgraduate medical training programs may wish to provide instruction concerning potential conflicts of interest inherent in these types of interactions.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health; University of Toronto

Mesh:

Year:  1995        PMID: 7641153      PMCID: PMC1487391     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  15 in total

1.  Pitching doctors.

Authors:  Michael S Wilkes; Miriam Shuchman
Journal:  N Y Times Mag       Date:  1989-11-05

2.  Teaching medical students to evaluate drug advertising.

Authors:  S GARB
Journal:  J Med Educ       Date:  1960-08

3.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education.

Authors:  M A Bowman; D L Pearle
Journal:  J Contin Educ Health Prof       Date:  1988       Impact factor: 1.355

4.  Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors.

Authors:  P R Lichstein; R C Turner; K O'Brien
Journal:  Arch Intern Med       Date:  1992-05

5.  Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives.

Authors:  W P McKinney; D L Schiedermayer; N Lurie; D E Simpson; J L Goodman; E C Rich
Journal:  JAMA       Date:  1990-10-03       Impact factor: 56.272

6.  Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff.

Authors:  N Lurie; E C Rich; D E Simpson; J Meyer; D L Schiedermayer; J L Goodman; W P McKinney
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

7.  Canadian Psychiatric Association guidelines in relating to the pharmaceutical industry.

Authors:  I E Carter
Journal:  Can J Psychiatry       Date:  1987-08       Impact factor: 4.356

8.  The role of commercial sources in the adoption of a new drug.

Authors:  M Y Peay; E R Peay
Journal:  Soc Sci Med       Date:  1988       Impact factor: 4.634

9.  Teaching drug promotion abuses to health profession students.

Authors:  P Palmisano; J Edelstein
Journal:  J Med Educ       Date:  1980-05

10.  Effect on student attitudes of a program of critical evaluation of claims for drugs.

Authors:  E E Daniel; L Leedham
Journal:  J Med Educ       Date:  1966-01
View more
  28 in total

1.  Pharmaceutical advertising revenue and physician organizations: how much is too much?

Authors:  P A Glassman; J Hunter-Hayes; T Nakamura
Journal:  West J Med       Date:  1999-10

2.  Managed care and ethical conflicts: anything new?

Authors:  C Meyers
Journal:  J Med Ethics       Date:  1999-10       Impact factor: 2.903

3.  Norwegian medical students' attitudes towards the pharmaceutical industry.

Authors:  Dordi Lea; Olav Spigset; Lars Slørdal
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

4.  Pharmacists' Perceptions of the Influence of Interactions with the Pharmaceutical Industry on Clinical Decision-Making.

Authors:  Aaron M Tejani; Peter Loewen; Richard Bachand; Curtis K Harder
Journal:  Can J Hosp Pharm       Date:  2015 Sep-Oct

5.  Factors affecting the opinions of family physicians regarding generic drugs--a questionnaire based study.

Authors:  Pawel Lewek; Janusz Smigielski; Przemyslaw Kardas
Journal:  Bosn J Basic Med Sci       Date:  2014-12-17       Impact factor: 3.363

Review 6.  Interactions between pharmaceutical representatives and doctors in training. A thematic review.

Authors:  Daniella A Zipkin; Michael A Steinman
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

7.  The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.

Authors:  Jathin Bandari; Robert M Turner; Bruce L Jacobs; David Canes; Ali Moinzadeh; Benjamin J Davies
Journal:  Urol Pract       Date:  2017-01

Review 8.  Bioethics for clinicians: 17. Conflict of interest in research, education and patient care.

Authors:  T Lemmens; P A Singer
Journal:  CMAJ       Date:  1998-10-20       Impact factor: 8.262

Review 9.  What information do physicians receive from pharmaceutical representatives?

Authors:  J Lexchin
Journal:  Can Fam Physician       Date:  1997-05       Impact factor: 3.275

10.  Japanese practicing physicians' relationships with pharmaceutical representatives: a national survey.

Authors:  Sayaka Saito; Kei Mukohara; Seiji Bito
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.